What are the recommended medical treatments for stress and urge urinary incontinence in women?

Medical Treatment for Stress and Urge Incontinence in Females

For stress incontinence, do NOT use systemic pharmacologic therapy—start with pelvic floor muscle training (PFMT) as first-line treatment; for urge incontinence, begin with bladder training and only add anticholinergic medications if behavioral therapy fails, selecting agents based on tolerability rather than efficacy since all are equally effective. 1

Treatment Algorithm by Incontinence Type

Stress Urinary Incontinence

First-Line: Non-Pharmacologic Only

• Pelvic floor muscle training (PFMT) is the definitive first-line treatment with high-quality evidence supporting its use 1
• Weight loss and exercise for obese women (strong recommendation, moderate-quality evidence) 1
• Avoid systemic pharmacologic therapy entirely for stress incontinence—the ACP explicitly recommends against it based on strong evidence 1

The evidence is clear: medications have no role in treating isolated stress incontinence. While duloxetine has been studied and is approved in some countries for female stress incontinence 2, 3, the ACP guideline strongly recommends against systemic pharmacologic therapy for this condition based on low-quality evidence of benefit 1.

Urge Urinary Incontinence

Step 1: Behavioral Therapy (Required First)

• Bladder training as initial treatment (strong recommendation, moderate-quality evidence) 1
• This must be attempted before considering medications

Step 2: Pharmacologic Therapy (Only if Bladder Training Fails)

When behavioral therapy is unsuccessful, add anticholinergic medications. The critical insight: all anticholinergics are equally effective, so selection should be based entirely on adverse effect profile, tolerability, ease of use, and cost 1.

Preferred agents based on discontinuation rates:

• Tolterodine or darifenacin: These are the only agents with discontinuation rates similar to placebo 1
• Solifenacin: Lowest risk for discontinuation among all antimuscarinics (high-quality evidence; NNTH 78) 1

Avoid as first-choice:

• Oxybutynin: Highest discontinuation rate due to adverse effects (NNTH 16) and most frequent dry mouth, constipation, and blurred vision 1
• Fesoterodine: High discontinuation rate (NNTH 33) 1

Alternative agents:

• Mirabegron (β3-adrenoceptor agonist): Different mechanism with different side effect profile (nasopharyngitis and GI disorders rather than anticholinergic effects) 1

Mixed Urinary Incontinence

Combined approach:

• PFMT plus bladder training together (strong recommendation, moderate-quality evidence) 1
• If behavioral therapy fails, consider pharmacologic therapy as per urge incontinence guidelines above

Key Evidence Considerations

Why behavioral therapy trumps medications: Recent network meta-analysis demonstrates that behavioral therapy is statistically significantly more effective than anticholinergics in achieving cure or improvement for urgency UI (high strength of evidence) 4. For stress UI, behavioral therapy outperforms both α-agonists and hormones (moderate strength of evidence) 4.

Common pitfalls to avoid:

1. Starting medications without adequate behavioral therapy trial—this violates evidence-based guidelines and exposes patients to unnecessary adverse effects
2. Choosing oxybutynin as first-line anticholinergic—despite being commonly prescribed, it has the worst tolerability profile
3. Using any systemic medication for isolated stress incontinence—there is no evidence supporting this approach
4. Assuming newer/more expensive anticholinergics work better—they don't; all are equally efficacious

Practical medication selection strategy: Since efficacy is equivalent across anticholinergics, start with tolterodine or darifenacin (placebo-level discontinuation rates), or solifenacin (lowest discontinuation among active agents). Reserve mirabegron for patients who cannot tolerate anticholinergic side effects (dry mouth, constipation, cognitive effects in elderly).

Special population considerations:

• Elderly women: Anticholinergics carry increased risk of cognitive impairment and should be used cautiously 5
• Obese women: Weight loss and exercise provide significant benefit and should be emphasized 1
• Women >65 years, nursing home residents: Represent vulnerable populations requiring careful medication selection based on adverse effect profiles 1